Lixisenatide Gains Evidence Of A Weight Loss Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi/Zealand's GLP-1 agonist lixisenatide continues to show promise in the latest GetGoal results, this time in type 2 diabetics inadequately controlled on sulfonylureas.